Quantum Biopharma Ltd. Approved to Dual List on Upstream
Quantum BioPharma (NASDAQ:QNTM) has received approval for dual listing on Upstream, a MERJ Exchange market and global securities trading app. Trading will commence on January 14, 2025, at 10:00am ET under the ticker 'QNTM'. The dual listing aims to provide access to a global investor base outside the U.S., enabling trading through various payment methods including credit/debit cards, PayPal, USD, or USDC.
The Upstream platform operates 20 hours daily, 7 days a week, featuring real-time trading and settlement with a transparent orderbook designed to prevent market manipulation. Non-U.S. investors can participate by downloading the Upstream app, completing KYC verification, and following specific share transfer procedures.
The company, which focuses on developing treatments for neurodegenerative and metabolic disorders, views this dual listing as a strategic move to enhance shareholder value by increasing liquidity and improving price discovery.
Quantum BioPharma (NASDAQ:QNTM) ha ricevuto l'approvazione per la doppia quotazione su Upstream, un mercato dell'MERJ Exchange e un'app globale per il trading di titoli. Le contrattazioni inizieranno il 14 gennaio 2025, alle 10:00 ET, con il ticker 'QNTM'. La doppia quotazione ha l'obiettivo di fornire accesso a una base di investitori globale al di fuori degli Stati Uniti, consentendo il trading attraverso vari metodi di pagamento tra cui carte di credito/debito, PayPal, USD o USDC.
La piattaforma Upstream opera 20 ore al giorno, 7 giorni su 7, con trading e liquidazione in tempo reale e un libro ordini trasparente progettato per prevenire manipolazioni di mercato. Gli investitori non statunitensi possono partecipare scaricando l'app Upstream, completando la verifica KYC e seguendo procedure specifiche per il trasferimento delle azioni.
L'azienda, che si concentra sullo sviluppo di trattamenti per disturbi neurodegenerativi e metabolici, considera questa doppia quotazione una mossa strategica per aumentare il valore per gli azionisti, migliorando la liquidità e facilitando la scoperta dei prezzi.
Quantum BioPharma (NASDAQ:QNTM) ha recibido la aprobación para una cotización dual en Upstream, un mercado del MERJ Exchange y una aplicación global de negociación de valores. La negociación comenzará el 14 de enero de 2025, a las 10:00 a.m. ET bajo el ticker 'QNTM'. La cotización dual tiene como objetivo proporcionar acceso a una base de inversores global fuera de EE. UU., permitiendo la negociación a través de diversos métodos de pago, incluyendo tarjetas de crédito/débito, PayPal, USD o USDC.
La plataforma Upstream opera 20 horas al día, 7 días a la semana, ofreciendo negociación y liquidación en tiempo real con un libro de órdenes transparente diseñado para prevenir la manipulación del mercado. Los inversores fuera de EE. UU. pueden participar descargando la aplicación Upstream, completando la verificación KYC y siguiendo procedimientos específicos para la transferencia de acciones.
La compañía, que se centra en el desarrollo de tratamientos para trastornos neurodegenerativos y metabólicos, ve esta cotización dual como un movimiento estratégico para aumentar el valor para los accionistas, mejorando la liquidez y facilitando la descubrimiento de precios.
퀀텀 바이오파마 (NASDAQ:QNTM)는 MERJ 거래소의 시장인 Upstream에 대한 이중 상장 승인을 받았습니다. 거래는 2025년 1월 14일 오전 10시 ET에 'QNTM'이라는 티커로 시작됩니다. 이중 상장의 목적은 미국 외의 글로벌 투자자 기반에 접근할 수 있도록 하여 신용카드/직불카드, PayPal, USD 또는 USDC를 포함한 다양한 결제 수단으로 거래를 가능하게 하는 것입니다.
Upstream 플랫폼은 매일 20시간, 주 7일 운영되며, 시장 조작을 방지하도록 설계된 투명한 주문서와 함께 실시간 거래 및 결제를 제공합니다. 미국 외 투자자는 Upstream 앱을 다운로드하고 KYC 인증을 완료한 후 특정 주식 이전 절차를 따르면 참여할 수 있습니다.
신경퇴행성 및 대사 장애 치료제 개발에 주력하는 이 회사는 주주 가치를 증가시키고 유동성을 개선하며 가격 발견을 용이하게 하는 전략적 조치로 이중 상장을 보고 있습니다.
Quantum BioPharma (NASDAQ:QNTM) a reçu l'approbation pour une double cotation sur Upstream, un marché de la MERJ Exchange et une application de négociation de titres à l'échelle mondiale. Les échanges commenceront le 14 janvier 2025 à 10h00 ET sous le ticker 'QNTM'. La double cotation vise à fournir un accès à une base d'investisseurs mondiale en dehors des États-Unis, permettant le trading via divers moyens de paiement, y compris cartes de crédit/débit, PayPal, USD ou USDC.
La plateforme Upstream fonctionne 20 heures par jour, 7 jours par semaine, offrant un trading et un règlement en temps réel avec un livre de commandes transparent conçu pour prévenir la manipulation du marché. Les investisseurs non américains peuvent participer en téléchargeant l'application Upstream, en complétant la vérification KYC et en suivant des procédures spécifiques de transfert d'actions.
L'entreprise, qui se concentre sur le développement de traitements pour les troubles neurodégénératifs et métaboliques, considère cette double cotation comme un mouvement stratégique pour améliorer la valeur actionnariale en augmentant la liquidité et en facilitant la découverte des prix.
Quantum BioPharma (NASDAQ:QNTM) hat die Genehmigung für eine Dual-Listing an Upstream, einem Markt der MERJ Exchange und einer globalen Handels-App für Wertpapiere, erhalten. Der Handel beginnt am 14. Januar 2025 um 10:00 Uhr ET unter dem Ticker 'QNTM'. Das Dual-Listing zielt darauf ab, den Zugang zu einer globalen Investorengruppe außerhalb der USA zu ermöglichen und den Handel über verschiedene Zahlungsmethoden wie Kredit-/Debitkarten, PayPal, USD oder USDC zu erlauben.
Die Upstream-Plattform ist 20 Stunden täglich, 7 Tage die Woche in Betrieb und bietet Echtzeit-Handel und -Abwicklung mit einem transparenten Orderbuch, das darauf ausgelegt ist, Marktmanipulationen zu verhindern. Nicht-US-Investoren können teilnehmen, indem sie die Upstream-App herunterladen, die KYC-Überprüfung abschließen und spezifische Verfahren für den Aktienübertragungsprozess befolgen.
Das Unternehmen, das sich auf die Entwicklung von Therapien für neurodegenerative und metabolische Erkrankungen konzentriert, betrachtet dieses Dual-Listing als einen strategischen Schritt zur Steigerung des Shareholder-Wertes, durch Erhöhung der Liquidität und Verbesserung der Preisdiskrepanz.
- Access to new global investor base outside U.S.
- Enhanced liquidity potential through additional trading venue
- Extended trading hours (20 hours daily, 7 days/week)
- Multiple payment options for trading (credit/debit, PayPal, USD, USDC)
- to non-U.S. investors for new trading venue
- Additional administrative steps required for existing shareholders to transfer shares
Insights
The dual listing of Quantum BioPharma on Upstream represents a strategic yet modest expansion of their market access. While this move enables broader international investor participation through modern payment methods like PayPal and USDC, the impact on immediate trading volume or valuation may be The 24/7 trading window and smart contract-powered platform offer enhanced liquidity opportunities, but Upstream's relative market size compared to NASDAQ suggests this is more about positioning than immediate financial impact.
The company's
The timing of this listing expansion aligns with broader trends in global market accessibility and digital asset integration. However, the operational impact needs careful consideration. While Upstream offers modern features like cryptocurrency payments and extended trading hours, its market depth and institutional participation levels are still developing. For a company of Quantum's size in the specialized biotech sector, the primary value proposition lies in geographic expansion rather than fundamental business enhancement.
The streamlined KYC process and mobile-first approach may attract retail investors, particularly in emerging markets, but institutional investors will likely continue to prefer traditional exchanges for large-volume transactions. This dual listing appears more focused on future-proofing market access than addressing immediate capital needs or liquidity constraints.
Trading to become available January 14th under 'QNTM'
TORONTO, ONTARIO / ACCESSWIRE / January 7, 2025 / Quantum BioPharma Ltd. (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) ("Quantum BioPharma" or the "Company"), today announced its approval to dual list its shares on Upstream, a MERJ Exchange market and global securities trading app. Trading becomes available on Upstream Tuesday, January 14, 2025, at 10:00am ET under the ticker symbol ‘QNTM.'
The dual listing on Upstream is designed to provide Quantum the opportunity to access a global investor base outside of the U.S. that can trade using a credit/debit card, PayPal, USD, or USDC; unlocking liquidity and enhancing price discovery while globalizing the opportunity to invest in the company.
Investors outside of the U.S. can get ready to trade by downloading Upstream from their preferred app store at https://upstream.exchange/, creating an account by tapping Sign Up, and completing a simple KYC identity verification by tapping the profile icon on the home screen and tapping KYC.
Existing non-U.S. shareholders may initiate the transfer of their shares by opening Upstream, tapping Investor, Manage Securities, Deposit Securities, then entering the ticker symbol ‘QNTM' and the number of shares to deposit, and tapping Submit. Next, investors enter their brokerage firm name and brokerage account number, then tap Submit. Lastly, investors tap Add E-Signature, sign their name on the screen using their finger, tap Done, and then tap Sign.
After completion of the deposit request on Upstream, shareholders will receive via email an executed deposit form to submit to their current brokerage firm to initiate a withdrawal to the transfer agent. Shares will not be transferred without notifying the current broker and requesting a withdrawal. On listing day, shareholders will receive a push notification once the shares are deposited and available for trading on Upstream.
Details on the Quantum listing, deposit, and trading instructions can be found at https://www.quantumbiopharma.com/investors. The Upstream market is open 7 days a week 20 hours a day, Monday to Sunday: 10:00am to 06:00am UTC+4 (1:00am to 9:00pm EST).
Traders on Upstream's smart contract-powered platform will experience real-time trading and settlement, and a transparent orderbook which does not permit common market manipulations.
Zeeshan Saeed, CEO of Quantum commented, "Building shareholder value is an ongoing goal of ours. We believe a dual listing on Upstream's next generation market supports this goal as we continue to develop our potential game changing drug candidates for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders that impact people from all over the world."
About Quantum BioPharma Ltd.
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. ("Lucid"), Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum BioPharma invented UNBUZZD™ and spun out its OTC version to a company, Celly Nutrition Corp. ("Celly Nutrition"), led by industry veterans. Quantum BioPharma retains ownership of
About Upstream
Upstream, a MERJ Exchange market (https://merj.exchange/), is a global securities trading app. Powered by Horizon's proprietary, transparency-first, matching engine, Upstream allows investors outside of the U.S. to trade securities using just an app. For more information, please visit https://upstream.exchange/. Upstream is currently accepting applications to dual list at https://upstream.exchange/getlisted.
Disclaimers
U.S. persons may not deposit, buy, or sell securities on Upstream.
This communication shall not constitute an offer to sell securities or the solicitation of an offer to buy securities in any jurisdiction where such offer or solicitation is not permitted. All orders for sale are non-solicited by Upstream and a user's decision to trade securities must be based on their own investment judgment.
Upstream is a MERJ Exchange market. MERJ Exchange is a licensed Securities Exchange, an affiliate of the World Federation of Exchanges, a National Numbering Agency, and a member of ANNA. MERJ is regulated in the Seychelles by the Financial Services Authority, https://fsaseychelles.sc/, an associate member of the International Association of Securities Commissions (IOSCO). MERJ supports global issuers of traditional and digital securities through the entire asset life cycle from issuance to trading, clearing, settlement, and registry. It operates a fair and transparent marketplace in line with international best practices and principles of operations of financial markets. Upstream does not endorse or recommend any public or private securities bought or sold on its app. Upstream does not offer investment advice or recommendations of any kind. All services offered by Upstream are intended for self-directed clients who make their own investment decisions without aid or assistance from Upstream. All customers are subject to the rules and regulations of their jurisdiction. By accessing the site or app, you agree to be bound by its terms of use and privacy policy. Company and security listings on Upstream are only suitable for investors who are familiar with and willing to accept the high risk associated with speculative investments, often in early and development-stage companies. U.S. persons may not deposit, buy, or sell securities on Upstream. There can be no assurance the valuation of any particular company's securities is accurate or in agreement with the market or industry comparative valuations. Investors must be able to afford market volatility and afford the loss of their investment. Companies listed on Upstream are subject to significant ongoing corporate obligations including, but not limited to disclosure, filings, and notification requirements, as well as compliance with applicable quantitative and qualitative listing standards.
Forward-Looking Information
This communication contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential," or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified, and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) difficulties in obtaining financing on commercially reasonable terms; (ii) changes in the size and nature of our competition; (iii) loss of one or more key executives or brand ambassadors; and (iv) changes in legal or regulatory requirements in the markets in which we operate. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
Contacts:
Quantum BioPharma Ltd.
Zeeshan Saeed, Founder, CEO and Executive Co-Chairman of the Board
Email: Zsaeed@quantumbiopharma.com
Telephone: (833) 571-1811
Investor Relations
Email: ir@quantumbiopharma.com, info@quantumbiopharma.com
Website: www.quantumbiopharma.com
SOURCE: Quantum Biopharma Ltd.
View the original press release on accesswire.com
FAQ
When will Quantum BioPharma (QNTM) start trading on Upstream?
What are the trading hours for QNTM on Upstream?
How can non-U.S. investors trade QNTM shares on Upstream?
What payment methods are accepted for trading QNTM on Upstream?
What is the purpose of QNTM's dual listing on Upstream?
